GlassScriptPhysician profile
Isaac Taylor Strong
NPI 1497478697
$5,591.22
in general payments reported to CMS, 2019-2025
17 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $219 · 2023: $1,920 · 2024: $1,563 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,267 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,266.77 |
| Education | $105.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $936.35 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $859.03 | 2022-2025 | Caplyta |
| Alkermes, INC. | $658.85 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $605.63 | 2023-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $547.75 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $404.11 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $387.95 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $280.09 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $251.92 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $222.95 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $125.71 | 2024-2025 | Qelbree |
| Tris Pharma INC | $84.89 | 2024-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $76.88 | 2022-2024 | Auvelity |
| Indivior INC. | $66.97 | 2024 | Perseris |
| Biogen, INC. | $38.76 | 2024-2025 | Zurzuvae |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.56 | 2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $19.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Strong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.